Post-marketing Surveillance (PMS) of GlaxoSmithKline Biologicals' 10-valent Pneumococcal Conjugate Vaccine (Synflorix) When Administered to Healthy Infants and Children According to the Prescribing Information in Sri Lanka

Trial Profile

Post-marketing Surveillance (PMS) of GlaxoSmithKline Biologicals' 10-valent Pneumococcal Conjugate Vaccine (Synflorix) When Administered to Healthy Infants and Children According to the Prescribing Information in Sri Lanka

Withdrawn prior to enrolment
Phase of Trial: Phase IV

Latest Information Update: 06 Sep 2013

At a glance

  • Drugs Pneumococcal 10-valent vaccine conjugate (Primary)
  • Indications Pneumococcal infections
  • Focus Adverse reactions
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 06 Sep 2013 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
    • 15 Mar 2013 Planned End Date changed from 1 Jan 2014 to 1 Apr 2014 as reported by ClinicalTrials.gov.
    • 15 Mar 2013 Planned initiation date (1 Apr 2013) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top